Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16769592rdf:typepubmed:Citationlld:pubmed
pubmed-article:16769592lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16769592lifeskim:mentionsumls-concept:C1527169lld:lifeskim
pubmed-article:16769592lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:16769592lifeskim:mentionsumls-concept:C0013018lld:lifeskim
pubmed-article:16769592lifeskim:mentionsumls-concept:C1504389lld:lifeskim
pubmed-article:16769592lifeskim:mentionsumls-concept:C0009647lld:lifeskim
pubmed-article:16769592lifeskim:mentionsumls-concept:C0680205lld:lifeskim
pubmed-article:16769592lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:16769592lifeskim:mentionsumls-concept:C1515895lld:lifeskim
pubmed-article:16769592pubmed:issue6lld:pubmed
pubmed-article:16769592pubmed:dateCreated2006-6-13lld:pubmed
pubmed-article:16769592pubmed:abstractTextWe describe our experience with the use of a single non-myeloablative preparative regimen in stem-cell transplantation (NST) in 37 heavily pretreated patients > or =55 years. The conditioning regimen consisted of fludarabine, low-dose busulfan, and antithymocyte globulin. Acute graft-versus-host disease (GVHD) grade III-IV and chronic GVHD developed in 15.6% and 44.4% of cases, respectively. With a median follow-up period of 22 (range 3-113) months, the 1-year overall survival and disease-free-survival were 55% and 53%, respectively, while the overall non-relapse mortality was 35%. In conclusion, reduced intensity stem cell transplantation is feasible and effective in patients > or =55 years. Age per se, should no longer be considered as a contra-indication to stem cell transplantation.lld:pubmed
pubmed-article:16769592pubmed:languageenglld:pubmed
pubmed-article:16769592pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16769592pubmed:citationSubsetIMlld:pubmed
pubmed-article:16769592pubmed:statusMEDLINElld:pubmed
pubmed-article:16769592pubmed:monthJunlld:pubmed
pubmed-article:16769592pubmed:issn1592-8721lld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:SlavinShimonSlld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:ResnickIgor...lld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:ShapiraMichae...lld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:GesundheitBen...lld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:TsirigotisPan...lld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:AckersteinAli...lld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:SamuelSimchaSlld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:ZilbermanIrin...lld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:MironSvetlana...lld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:BitanReuven...lld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:EladìSharonSlld:pubmed
pubmed-article:16769592pubmed:authorpubmed-author:LeubovicAlexa...lld:pubmed
pubmed-article:16769592pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16769592pubmed:volume91lld:pubmed
pubmed-article:16769592pubmed:ownerNLMlld:pubmed
pubmed-article:16769592pubmed:authorsCompleteYlld:pubmed
pubmed-article:16769592pubmed:pagination852-5lld:pubmed
pubmed-article:16769592pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:meshHeadingpubmed-meshheading:16769592...lld:pubmed
pubmed-article:16769592pubmed:year2006lld:pubmed
pubmed-article:16769592pubmed:articleTitleA non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients.lld:pubmed
pubmed-article:16769592pubmed:affiliationDepartment of Bone Marrow Transplantation & Cancer Immunotherapy, Hadassah, Hebrew University Medical Center, Jerusalem, Israel.lld:pubmed
pubmed-article:16769592pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16769592pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16769592pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16769592lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16769592lld:pubmed